A phase 2, multicentre, open-label, single arm study to evaluate theeffectiveness and safety of rezafungin (as acetate) in the treatment of chronic pulmonaryaspergillosis (CPA) in patients with limited treatment options.

• Protocol code: MR907-2502
• EudraCT code: No aplica
• Research group: Infectious Diseases
• Service: Infectious
• Principal investigator:  Len Abad, Oscar
• Pathology: Certes malalties infeccioses i parasitàries
• Phase: Fase II

Estudio de fase 2b, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de tulisokibart en participantes con hidradenitis supurativa moderada o grave

• Protocol code: MK-7240-012
• EudraCT code: No aplica
• Service: Dermatologia
• Principal investigator:  Mollet Sánchez, Jordi
• Pathology: Malalties de la pell i del teixit subcutani
• Phase: Fase II

AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 3,DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE ORALLY ADMINISTEREDIBUZATRELVIR COMPARED WITH PLACEBO IN NON-HOSPITALIZEDSYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID-19 WHOARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS

• Protocol code: C5091017
• EudraCT code: No aplica
• Research group: Infectious Diseases
• Service: Infectious
• Principal investigator:  Len Abad, Oscar
• Pathology: Certes malalties infeccioses i parasitàries
• Phase: Fase III

Estudio de fase Ib, abierto y de dosis ascendente para evaluar la seguridad, la tolerabilidad y la farmacocinética de PIT565 en participantes con artritis reumatoide (AR).

• Protocol code: CPIT565C12101
• EudraCT code: No aplica
• Research group: Rheumatology
• Service: Rheumatology
• Principal investigator:  Lopez Lasanta, Maria America
• Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
• Phase: Fase I

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Nebulized Bacteriophage Treatment in Outpatient Adult Cystic Fibrosis (CF) Subjects with Chronic Pseudomonas aeruginosa (PsA) Pulmonary Infection

• Protocol code: BMX-04-002
• EudraCT code: No aplica
• Research group: Shock, Organ Dysfunction and Resuscitation
• Service: RTA ICU
• Principal investigator:  Alvarez Gonzalez, Antonio
• Pathology: Certes malalties infeccioses i parasitàries
• Phase: Fase II

A phase?3, randomized, double-blind, Placebo-controlled study to evaluate the efficacy and safety of orally administered deucrictibant extended-release tablet for Prophylaxis against angioedema attacks in adolescents and adults with hereditary angioedema.

• Protocol code: PHA022121-C305
• EudraCT code: _
• Research group: Systemic Diseases
• Service: Internal Medicine
• Principal investigator:  Guilarte Clavero, Mar
• Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
• Phase: Fase III